OAG
3.1.2020 10:02:03 CET | Business Wire | Press release
OAG , the world’s leading provider of travel data and insight, today released the results of the OAG Punctuality League 2020 , a comprehensive ranking of the world’s largest airlines and airports for on-time performance (OTP).
Aeroflot finished as the most punctual Mega Airline in Europe and second-most punctual mega in the world (OTP 86.30%). Five additional European carriers earned spots among the world’s Top 20 Mega Airlines, including Air France (7th ; OTP 79.92%), British Airways (14th ; OTP 76.18%), Lufthansa (15th ; OTP 73.96%) and easyJet (17th ; OTP 73.08%).
Jet2 (OTP 82.69%), the UK’s third-largest airline, ranked fifth among the Top 20 Low-Cost Carriers (LCCs) and finished 19th globally. Several other European carriers, including Iberia (11th ; OTP 84.06%), Siberia Airlines (12th ; OTP 83.88%) and Air Baltic (13th ; OTP 83.63%) also placed among the world’s most punctual airlines.
British Airways’ hub London Heathrow (LHR; OTP 75.27%) ranked 13th among Mega Airports—a notable accomplishment for the world’s most internationally connected airport .
“The global market is reaching near peak OTP,” said John Grant, senior analyst with OAG. “The rise in performance is led by Mega Airlines like Aeroflot, Delta and Air France, which are simultaneously expanding the number of operated flights and maintaining high OTP. We’re seeing success trickle down to the hubs they service, which benefits the entire travel ecosystem.”
Delta (OTP 83.56%) ranked as the No. 1 Mega Airline in the continental U.S. for a third-straight year. Atlanta Hartsfield-Jackson (4th , ATL; OTP 83.74%) led the list of Delta hubs placing among the world’s most on-time Mega Airports. The top three Mega Airports in the world were Moscow Sheremetyevo (SVO; OTP 86.87%), Tokyo Haneda (HND; OTP 86.60%), and Singapore Changi (SIN; OTP 84.03%). Los Angeles International (LAX; OTP 79.62%) and New York’s John F. Kennedy (JFK; OTP 77.87%) ranked 7th and 8th , respectively.
Download the full report for more insights from OAG’s Punctuality League 2020 .
About OAG
OAG is a leading global travel data provider, that has been powering the growth and innovation of the air travel ecosystem since 1929. OAG has global operations in the UK, USA, Singapore, Japan, Lithuania and China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200103005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom